Posted On: 11/18/2014 9:44:15 AM
Post# of 30034
Re: biotechexpert #11160
I think it's clear Gerald wanted to wrap up this call prior to the market opening. With 2 minutes remaining, he elected to take one more question, and the Edison analyst asked several questions, which pushed the presentation over by several minutes after the market opened.
It was a long call, but those listening now have a very good understanding of the reasons for acquiring the ESS-W asset as well as the path forward. With that being said, I'm sure the armchair CEOs will find fault with something. Some wanted questions answered about LymPro, but it's clear this wasn't the focus point of the call. There were updates on LymPro progress to include the fact that everything remains on track, but the analyst questions focused on the ESS acquisition, and rightfully so.
It was a long call, but those listening now have a very good understanding of the reasons for acquiring the ESS-W asset as well as the path forward. With that being said, I'm sure the armchair CEOs will find fault with something. Some wanted questions answered about LymPro, but it's clear this wasn't the focus point of the call. There were updates on LymPro progress to include the fact that everything remains on track, but the analyst questions focused on the ESS acquisition, and rightfully so.
(0)
(0)Scroll down for more posts ▼
